Sun Pharma to acquire Daiichi's 11.28 percent stake in Zenotech

After the acquisition, Sun Pharma's stake in Zenotech will increase from 57.56 percent to 68.84 percent.

Published On 2022-03-22 11:04 GMT   |   Update On 2022-03-22 13:18 GMT
Advertisement

New Delhi: Sun Pharmaceutical Industries on Monday said it has entered into a share purchase agreement with Japan's Daiichi Sankyo Company to acquire the latter's 11.28 percent stake in Zenotech Laboratories. Sun Pharma said it will pay ₹5.32 crore for the stake.

The primary objective of the transaction from acquirer's perspective is to consolidate its holding in the target company, the Mumbai-based drug firm said in a regulatory filing.
Advertisement
After the acquisition, Sun Pharma's stake in Zenotech will increase from 57.56 percent to 68.84 percent, it added.
Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Sun Pharma manufacture and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year. 
The core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development. 

The company's capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled release dosage forms. The R&D is led by a strong team of more than 2000 scientists.






Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News